Literature DB >> 30979631

Compendium of fractionation choices for gynecologic HDR brachytherapy-An American Brachytherapy Society Task Group Report.

Kevin Albuquerque1, Brian A Hrycushko2, Matthew M Harkenrider3, Jyoti Mayadev4, Ann Klopp5, Sushil Beriwal6, Daniel G Petereit7, Daniel J Scanderbeg4, Catherine Yashar4.   

Abstract

PURPOSE: The purpose of this study was to report a list of accepted fractionation schemes for high-dose-rate (HDR) brachytherapy for gynecological cancers in a definitive, neoadjuvant, or adjuvant setting. METHODS AND MATERIALS: Members of the American Brachytherapy Society (ABS) Task Force with expertise in gynecological brachytherapy reviewed the literature and existing ABS guidelines regarding various dose-fractionation schedules for HDR brachytherapy to create this compendium. Other resources include current guidelines published by medical societies, clinical trials, the published medical literature, and the clinical experience of the ABS Task Force members. The ABS consensus statements for HDR brachytherapy practice were reviewed for these fractionation schemes and form the major source for this report. Specific recommendations for therapy and recommendations for further investigations were made when there was agreement.
RESULTS: A variety of dose-fractionation schedules for HDR brachytherapy alone or integrating brachytherapy with external-beam radiation exist. The choice of a given fractionation schedule may be appropriate depending on the practice situation for the patient and the resources available. While there is no single optimal dose-fractionation scheme for any disease site or clinical situation, higher doses per fraction with fewer fractions per regimen have been known to increase toxicity. The corresponding 2-Gray (Gy) per fraction radiobiologic equivalent doses have been provided (normalized therapy dose) to compare the various regimens where indicated and can be used to estimate isoeffective schedules.
CONCLUSIONS: This compendium of HDR brachytherapy fractionation schedules provides various options to the gynecologic brachytherapist and a ready reference for clinical use in the management of gynecological cancer treatments.
Copyright © 2019 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brachytherapy; Consensus; Fractionation; Gynecological cancer

Year:  2019        PMID: 30979631     DOI: 10.1016/j.brachy.2019.02.008

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  17 in total

1.  Stereotactic Body Radiation Therapy Boost in Patients With Cervical Cancer Ineligible for Brachytherapy.

Authors:  Giuseppe Facondo; Gianluca Vullo; Vitaliana DE Sanctis; Maurizio Valeriani; Anna Maria Ascolese; Maria Massaro; Dimitri Anzellini; Mattia Falchetto Osti
Journal:  Cancer Diagn Progn       Date:  2021-05-03

2.  Proposed brachytherapy recommendations (practical implementation, indications, and dose fractionation) during COVID-19 pandemic.

Authors:  Pranshu Mohindra; Sushil Beriwal; Mitchell Kamrava
Journal:  Brachytherapy       Date:  2020-05-01       Impact factor: 2.362

3.  Evaluation of deformable image registration algorithm for determination of accumulated dose for brachytherapy of cervical cancer patients.

Authors:  Reza Mohammadi; Seied Rabi Mahdavi; Ramin Jaberi; Zahra Siavashpour; Leila Janani; Ali Soleimani Meigooni; Reza Reiazi
Journal:  J Contemp Brachytherapy       Date:  2019-10-30

4.  COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation.

Authors:  Vonetta M Williams; Jenna M Kahn; Matthew M Harkenrider; Junzo Chino; Jonathan Chen; L Christine Fang; Emily F Dunn; Emma Fields; Jyoti S Mayadev; Ramesh Rengan; Daniel Petereit; Brandon A Dyer
Journal:  Brachytherapy       Date:  2020-04-21       Impact factor: 2.362

5.  The Case for Brachytherapy: Why It Deserves a Renaissance.

Authors:  Vonetta M Williams; Jenna M Kahn; Nikhil G Thaker; Sushil Beriwal; Paul L Nguyen; Douglas Arthur; Daniel Petereit; Brandon A Dyer
Journal:  Adv Radiat Oncol       Date:  2020-11-06

6.  High-dose-rate interstitial brachytherapy with hypoxic radiosensitizer KORTUC II for unresectable pelvic sidewall recurrence of uterine cervical cancer: a case report.

Authors:  Mio Nakata; Ken Yoshida; Taiju Shimbo; Nobuhiko Yoshikawa; Hiroto Yoshioka; Akihiro Hori; Chikara Sato; Yasuo Uesugi; Yuhei Kogata; Koji Masui; Naoya Murakami; Tairo Kashihara; Hironori Akiyama; Nikolaos Tselis; Masahide Ohmichi; Keiji Nihei
Journal:  J Contemp Brachytherapy       Date:  2020-12-16

7.  High-dose-rate brachytherapy boost for locally advanced cervical cancer: Oncological outcome and toxicity analysis of 4 fractionation schemes.

Authors:  Maud le Guyader; Daniel Lam Cham Kee; Brice Thamphya; Renaud Schiappa; Mathieu Gautier; Marie-Eve Chand-Fouche; Jean-Michel Hannoun-Levi
Journal:  Clin Transl Radiat Oncol       Date:  2021-11-06

8.  Vaginal cuff brachytherapy: do we need to treat to more than a two-centimeter active length?

Authors:  Garrett L Jensen; Parul N Barry; Harriet Eldredge-Hindy; Scott R Silva; Sarah L Todd; Kendall P Hammonds; Walker R Zimmerman; Daniel S Metzinger; Moataz N El-Ghamry
Journal:  J Contemp Brachytherapy       Date:  2021-05-07

9.  Brachytherapy during the coronavirus disease 2019 - Lessons from Iran.

Authors:  Mahdi Aghili; Fatemeh Jafari; Mojtaba Vand Rajabpoor
Journal:  Brachytherapy       Date:  2020-05-14       Impact factor: 2.362

10.  One-week vaginal brachytherapy schedule as exclusive adjuvant post-operative treatment in intermediate- and high-intermediate-risk endometrial cancer patients.

Authors:  Vitaliana De Sanctis; Daniela Musio; Francesca De Felice; Francesco Marampon; Maurizio Valeriani; Paolo Bonome; Dimitri Anzellini; Giuseppe Facondo; Gianluca Vullo; Maria Massaro; Mario Di Staso; Pierluigi Bonfili; Agnieszka Chalaszczyk; Giovanni Luca Gravina; Vincenzo Tombolini; Mattia Falchetto Osti
Journal:  J Contemp Brachytherapy       Date:  2020-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.